Discovery STAR Award - Supporting Translational Research

Picture of a cup.  Domainex presents its Discovery STAR Award for Translational Research

Domainex is committed to the support of exciting and cutting-edge translational research. From the time of its formation by The Institute of Cancer Research (ICR), Birkbeck College and UCL, to its present work with Imperial College London, St George’s University of London, The Universities of Manchester and Leeds, and the ICR, Domainex has exemplified how academic-private sector drug discovery collaborations can succeed and be beneficial to all parties.

Eddy Littler, Domainex's CEO speaking about the first recipient of the Discovery STAR award


Domainex launched its Discovery STAR award in 2013, to support the early stages of drug discovery for a chosen number of applicants to the scheme. At Domainex’s discretion, the selected applicants will be provided with drug discovery advice and/or virtual hit screening free of charge in order to bridge the gap between academic grants and drug discovery funding schemes such as the Wellcome Trust SDDI, Technology Strategy Board, Biomedical Catalyst Fund, or MRC DPFS 2.

  • Domainex will open the Discovery STAR award to applications once per year. The deadline for the next round is shown below. If you have questions, please contact George Buckley at
  • Domainex will treat any information provided as confidential, but is willing to enter into a non-disclosure agreement with an applicant if this is preferred.

In order to apply, please provide us with the following details and email your application to


Details to Include in Your STAR Award Application

  • Name, position, academic institute

In relation to your drug discovery programme, please explain to us why a Discovery STAR Award would be of benefit.  Please also include information such as:

  • Description of novelty of drug target or mechanism
  • Does the project address a significant unmet medical need? Please explain the novelty of your approach to this disease indication.
  • Are assays established to enable testing of the screening set that will be proposed by Domainex following the award? Are these assays already established within your laboratories? Please describe in detail the format and throughput of this assay and the source of reagents.
  • Is information available to enable a virtual screen?  For example: structural information regarding the target, or of orthologous or homologous proteins; or information about known ligands/inhibitors.
  • In the event that you are awarded free Virtual screening services, this will result in the selection of a compound screening set, tailored to your target and clinical indication. Do you already have funding available to enable the purchase of min. 200-500 compounds from 3rd parties at an average of £30/cpd, or will you seek additional funds to support this?
  • What is your plan following successful hit identification?  For example, do you intend to attract further funding to support a larger drug discovery project?
  1. No compound purchase from 3rd party suppliers is included and the cost of these must be found by the award recipient.
  2. No cash alternatives to the award are available.